Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARROW, INC.HROW · Entity 4740 | CHIEF SCIENTIFIC OFFICER | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARROW, INC.
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,250 |
Reported balance
After 2026-08-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-14 · Exercise / conversion · Acquired 11,250 · Balance 11,250 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-14 · Sale · Disposed 11,250 · Balance 0 F1: The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.96 · Expires 2035-01-06 | Direct | 18,750 |
Reported balance
After 2026-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-14 · Exercise / conversion · Disposed 11,250 · Balance 18,750 F2: The option was granted on January 6, 2025. The shares subject to the option vest according to the following schedule: 25% of the shares vested at the one-year anniversary of the date of grant, and the remaining shares vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029. F1: The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise.
F2: The option was granted on January 6, 2025. The shares subject to the option vest according to the following schedule: 25% of the shares vested at the one-year anniversary of the date of grant, and the remaining shares vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 21:47 UTC | HARROW, INC. HROW · Entity 4740 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,250 | $35.96 Strike: $35.96 | $404,550.00 |
DisclosureSEC source: 0001493152-26-038807 · ownership.xml · derivative · entry 3 Shojaei Amir · CIK 0002051427 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 11,250 shares Expires 2035-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The option was granted on January 6, 2025. The shares subject to the option vest according to the following schedule: 25% of the shares vested at the one-year anniversary of the date of grant, and the remaining shares vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029. F1 · derivative.exercise_date: The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 21:47 UTC | HARROW, INC. HROW · Entity 4740 | SaleCommon Stock | 11,250 | $40.00 | $450,000.00 |
DisclosureSEC source: 0001493152-26-038807 · ownership.xml · nonDerivative · entry 2 Shojaei Amir · CIK 0002051427 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 21:47 UTC | HARROW, INC. HROW · Entity 4740 | Exercise / conversionCommon Stock | 11,250 | $35.96 | $404,550.00 |
DisclosureSEC source: 0001493152-26-038807 · ownership.xml · nonDerivative · entry 1 Shojaei Amir · CIK 0002051427 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:00 UTC | HARROW, INC. HROW · Entity 4740 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-024208 · ownership.xml · derivative · entry 1 Shojaei Amir · CIK 0002051427 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · security: Each restricted stock unit represents a contingent right to receive one share of Harrow, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on May 15, 2029, subject to the Reporting Person's continued service through such date. F2 · derivative.expiration_date: The restricted stock units vest in full on May 15, 2029, subject to the Reporting Person's continued service through such date. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:33 UTC | HARROW, INC. HROW · Entity 4740 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $35.96 | $0.00 |
DisclosureSEC source: 0001493152-25-001478 · ownership.xml · derivative · entry 1 Shojaei Amir · CIK 0002051427 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-01-06 F1 · security: The shares subject to the option shall vest according to the following schedule: 25% of the shares shall vest at the one-year anniversary of the date of grant, and the remaining shares shall vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029. F1 · derivative.exercise_date: The shares subject to the option shall vest according to the following schedule: 25% of the shares shall vest at the one-year anniversary of the date of grant, and the remaining shares shall vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.